These issues may also lead to patient non-compliance and thus, reduced efficacy," said .
"Somavaratan may offer the least frequent dosing schedule with twice-monthly dosing, and with the Phase 3 VELOCITY trial now fully enrolled, it may be the first of the long-acting growth hormone preparations currently in development to become available for children with GHD." "We are grateful to the patients and their families as well as the investigators who are taking part in VELOCITY.
• Only studio owners and directors can register students for an event.
As with patients who completed the prior Phase 2 trial of somavaratan in pediatric GHD, patients completing the Phase 3 VELOCITY trial will have the opportunity to transition to an ongoing, open-label, long-term safety study named VISTA ( Annual Meeting in Q2 2016.
Somavaratan's twice-monthly dosing schedule is the least frequent dosing interval in development for long-acting growth hormones.
Please select the "back" button in your browser and try again.
(NASDAQ: VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rh GH) for growth hormone deficiency (GHD), today announced the completion of enrollment in the Phase 3 VELOCITY trial of somavaratan in pediatric GHD.
About Somavaratan Somavaratan is investigational, novel, long-acting form of recombinant human growth hormone (rh GH).
This fusion protein consists of rh GH and specific sequences of naturally-occurring hydrophilic amino acids based on a proprietary XTEN®technology.(For example: Ages for October 2017 events will be as of January 1st 2018, and ages for March 2018 events will be as of January 1st 2018.)• All registration and entry fees are non-refundable, no exceptions.• All registration must be completed four weeks before the convention to receive the discounted rate.Please refer to the deadline dates posted next to the city in which you are attending.We look forward to completing this Phase 3 trial and reporting top-line results around this time next year," said .This study enrolled naïve to treatment, pre-pubertal children with GHD who were randomized 3:1 to 3.5 mg/kg of somavaratan twice-monthly or daily rh GH at 34 µg/kg/day, the highest approved GHD dose on the labels of Genotropin.Somavaratan has been designed with the goal of improving therapeutic outcomes for children and adults with growth hormone deficiency (GHD), including enhanced compliance and convenience with a twice-monthly dosing schedule, fine gauge needle autoinjector device and room temperature storage.